Drugs / AKB-9778
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04284514 | May → Dec 2019 | ocular hypertension, open-angle glaucoma | Aerpio Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02858271 | Jul 2016 | — | Aerpio Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01702441 | Sep 2012 → Sep 2013 | diabetic macular edema | Aerpio Therapeutics | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04405245 | Jun → Nov 2020 | ocular hypertension, open-angle glaucoma | EyePoint Pharmaceuticals, Inc. | Completed | Mixed |
| Phase 2 | NCT03197870 | Jun 2017 → Jan 2019 | diabetic retinopathy | EyePoint Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT02387788 | Jan 2015 → Apr 2017 | retinal vein occlusion | Aerpio Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02050828 | Jan 2014 → Apr 2015 | diabetic macular edema | Aerpio Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKB-9778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02858271 ↗ |
| Known as | Razuprotafib | “AKB-9778 (Razuprotafib), a Novel Tie 2 Activator” NCT03197870 ↗ |
| Action | Activate | “AKB-9778, a Novel Tie-2 Activator” NCT02050828 ↗ |
| Route | Subcutaneous | “given as subcutaneous injections” NCT01702441 ↗ |